Postprandial dyslipidemia: An atherogenic disorder common in patients with diabetes mellitus

American Journal of Cardiology

Volumn 88, Issue 2 SUPPL. 2, 2001, Pages

  Ginsberg, Henry N ^a,c   Illingworth, D Roger ^b  

^a Columbia University ^*  (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; CHYLOMICRON; DOCOSAHEXAENOIC ACID; FIBRIC ACID DERIVATIVE; FISH OIL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; LONG CHAIN FATTY ACID; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ENZYME INHIBITOR; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIVER ENZYME;

ATHEROGENESIS; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR RISK; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EXERCISE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; LIPOPROTEIN METABOLISM; LIVER TOXICITY; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; ATHEROSCLEROSIS; CLINICAL TRIAL; CONFERENCE PAPER; DIABETIC DIET; LIPID ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL VALUE; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

ANTILIPEMIC AGENTS; CORONARY ARTERIOSCLEROSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; HYPERLIPIDEMIAS; POSTPRANDIAL PERIOD;

EID: 0035954846     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9149(01)01831-8     Document Type: Review

References (55)

1. Lipids, diabetes, and coronary heart disease: Insights from the Framingham study
2. Diabetes, other risk factors and 12-yr mortality for men screened in the multiple risk factor intervention trial
3. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarctions
4. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry
5. Lipoprotein physiology in nondiabetic and diabetic states: Relationship to atherogenesis
6. Lipoprotein physiology
7. Plasma lipid transfer proteins, high-density lipoproteins, and reverse cholesterol transport
8. Influence of lipolysis on chylomicron clearance and HDL cholesterol levels
9. Hyperlipidemia and diabetes mellitus
10. Syndrome X: Six years later
11. Detection and management of lipid disorders in diabetes
12. Aortic accumulation and plasma clearance of beta-VLDL and HDL: Effects of diet-induced hypercholesterolemia in rabbits
13. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque
14. Atherosclerosis and arterial influx of lipoproteins
15. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study
16. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): Questions, quandaries, and paradoxes
17. Chylomicrons and chylomicron remnants in coronary artery disease: A case-control study
18. Postprandial lipoprotein metabolism and atherosclerosis
19. Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women
20. Relation of triglyceride metabolism and coronary artery disease: Studies in the postprandial state
21. Postprandial lipemia: Emerging evidence for atherogenicity of remnant lipoproteins
22. Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women
23. Postprandial triglyceridemia and carotid atherosclerosis in middle-aged subjects
24. Magnitude of alimentary lipemia is related to intima-media thickness of the common carotid artery in middle-aged men
25. Echolucent carotid artery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins
26. Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men
27. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. (Adult Treatment Panel III)
28. Management of dyslipidemia in adults with diabetes
29. Standards of medical care for patients with diabetes
30. Hypertriglyceridemia: A contraindication to the use of bile acid binding resins
31. Management of hypercholesterolemia
32. Effect of statins on triglyceride metabolism
33. The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia
34. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia
35. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: Scandinavian Simvastatin Survival Study
36. The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: The Cholesterol and Recurrent Events investigators
37. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
38. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group
39. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study
40. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)
41. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial. The CARE Investigators
42. Pravastatin therapy and the risk of stroke
43. Post-prandial metabolism of triglyceride-rich lipoproteins in non-insulin-dependent diabetic patients before and after bezafibrate treatment
44. Fibric acid derivatives
45. Mechanism of action of fibrates
46. Clinical results with gemfibrozil and background to the Helsinki Heart Study
47. Effects of fibric acid derivatives and metformin on postprandial lipemia
48. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary disease
49. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Study Group
50. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus
51. Fulminant hepatic failure after ingestion of sustained release nicotinic acid
52. Effects of fish oil on VLDL triglyceride kinetics in humans
53. Effects of n-3 fatty acids on postprandial triacylglycerol and hormone concentrations in normal subjects
54. Reduction of postprandial triglyceridemia in humans by dietary n-3 fatty acids
55. Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n-3 fatty acids